checkAd

     139  0 Kommentare Liquidia to Present at the Jefferies Virtual Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:30am Eastern time.

    A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.

    About Liquidia

    Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

    Contact Information

    Investor Relations:
    Jason Adair
    Vice President, Corporate Development and Strategy
    919.328.4400
    jason.adair@liquidia.com

     




    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Liquidia to Present at the Jefferies Virtual Healthcare Conference RESEARCH TRIANGLE PARK, N.C., May 27, 2020 (GLOBE NEWSWIRE) - Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary …